Skip to main content
Back to homepage
Menu

Press Releases

Press release year list 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012
May 12, 2022
ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress
May 09, 2022
ADC Therapeutics Announces CEO Transition
May 09, 2022
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 04, 2022
ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
May 03, 2022
ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022
April 04, 2022
ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services
March 17, 2022
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021
March 03, 2022
ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
March 01, 2022
ADC Therapeutics to Participate in Cowen’s 42nd Annual Health Care Conference
February 24, 2022
ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022
February 17, 2022
ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report
February 08, 2022
ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline
February 02, 2022
ADC Therapeutics to Participate in Guggenheim Oncology Conference
January 20, 2022
ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022
January 18, 2022
ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan